OGP
PreclinicalEndogenous osteogenic peptide
Research material. Not for human or animal consumption.
Research overview
Osteogenic growth peptide (OGP) is a 14-amino-acid peptide found in blood, first identified in regenerating bone marrow in 1992. Its sequence is identical to the C-terminal end of histone H4, and it is produced from an alternative start site in histone H4 messenger RNA. OGP stimulates the growth and activity of osteoblasts, and its active core is the C-terminal pentapeptide OGP(10-14). Research covers bone formation, fracture healing, bone graft materials and recovery of blood cell production after marrow injury in animals.
Laboratory, computational, ex vivo or animal model research is the main evidence base.
Questions about OGP
PRODUCT QUESTIONSWhat is OGP?
OGP is a 14 residue peptide identical to the C terminal residues of histone H4. Its shortest active fragment is the pentapeptide tyrosine, glycine, phenylalanine, glycine, glycine.
What research has been published on OGP?
Laboratory and animal studies examined osteoblast growth, bone mass, fracture healing and the coating of bone graft materials, as well as haematopoietic recovery after marrow ablation. Human data are minimal, so evidence remains preclinical.
What batch documentation should accompany OGP?
OGP: Ask for the COA and analytical reports for the batch being quoted. Ask for mass spectrometry, HPLC purity, peptide content and a statement of whether the full peptide or the active pentapeptide fragment is supplied.
How should OGP storage conditions be assessed?
Store OGP lyophilised at −20°C, dry and protected from light. Prepare solutions shortly before use, especially for coating scaffolds, where stability over time should be tested.